| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Alpha-2A adrenergic receptor |
|---|
| Ligand | BDBM50179393 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_1583766 (CHEMBL3815853) |
|---|
| Ki | 4.4±n/a nM |
|---|
| Citation |  Vucicevic, J; Srdic-Rajic, T; Pieroni, M; Laurila, JM; Perovic, V; Tassini, S; Azzali, E; Costantino, G; Glisic, S; Agbaba, D; Scheinin, M; Nikolic, K; Radi, M; Veljkovic, N A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin. Bioorg Med Chem24:3174-83 (2016) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Alpha-2A adrenergic receptor |
|---|
| Name: | Alpha-2A adrenergic receptor |
|---|
| Synonyms: | ADA2A_HUMAN | ADRA2A | ADRA2R | ADRAR | Adrenergic alpha2A | Adrenergic receptor alpha | Alpha-2 adrenergic receptor subtype C10 | Alpha-2A adrenoceptor | Alpha-2A adrenoreceptor | Alpha-2AAR | alpha-2A adrenergic receptor [Homo sapiens] |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 48979.91 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P08913 |
|---|
| Residue: | 465 |
|---|
| Sequence: | MFRQEQPLAEGSFAPMGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLML
LTVFGNVLVIIAVFTSRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAW
CEIYLALDVLFCTSSIVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVIS
FPPLISIEKKGGGGGPQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKR
RTRVPPSRRGPDAVAAPPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGP
RDTDALDLEESSSSDHAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTP
AAGPGEERVGAAKASRWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPR
TLFKFFFWFGYCNSSLNPVIYTIFNHDFRRAFKKILCRGDRKRIV
|
|
|
|---|
| BDBM50179393 |
|---|
| n/a |
|---|
| Name | BDBM50179393 |
|---|
| Synonyms: | Efaroxan |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C13H16N2O |
|---|
| Mol. Mass. | 216.2789 |
|---|
| SMILES | CCC1(Cc2ccccc2O1)C1=NCCN1 |t:13| |
|---|
| Structure | 
|
|---|
Search and Browse
